June 6, 2011 (Washington, DC) — A post hoc analysis of a phase 3 clinical trial of the acute migraine drug dihydroergotamine (Levadex, MAP Pharmaceuticals Inc) using 4 different previously published ...
To determine whether a variable definition of biochemical recurrence (BCR) based on clincopathologic features facilitates early identification of patients likely to suffer from disease progression.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback